Milan, Italy: The adjunctive use of whole-plant medical cannabis extracts is associated with improvements in symptom management in patients with fibromyalgia (FM), according to clinical data published in the journal Clinical and Experimental Rheumatology.
A team of Italian investigators assessed the administration of cannabis extracts in 102 FM patients who had not previously responded favorably to conventional medical treatments. The adjunctive use of cannabis over a six-month period was associated with improvements in patients’ anxiety and depression in half of the study’s participants. Just under half of subjects reported improvements in sleep, and a third acknowledged a reduction in overall disease severity.
Authors concluded, "This observational study shows that adjunctive MCT (medical cannabis treatment) offers a possible clinical advantage in FM patients, especially in those with sleep dysfunctions."
Full text of the study, "Adding medical cannabis to standard analgesic treatment for fibromyalgia: A prospective observational trial," appears in Clinical and Experimental Rheumatology. Additional information on cannabinoids and fibromyalgia is available online.